Lenalidomide Sandoz (Lenalidomide)

• Lenalidomide is indicated for several hematologic malignancies where it modulates disease pathways.
• Multiple Myeloma: improves progression‑free survival when combined with dexamethasone in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality.
• Mantle Cell Lymphoma: contributes to disease control as part of combination therapy in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination of transcription factors such as Ikaros and Aiolos. This leads to reduced proliferation of malignant plasma cells, enhanced immune‑mediated tumor cell clearance, and inhibition of angiogenesis, collectively exerting antineoplastic activity.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count, increasing infection risk.
• Thrombocytopenia: reduced platelet count, may cause bleeding.
• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools, may lead to dehydration.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention.
• Secondary primary malignancies: emergence of new cancers unrelated to the original disease.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, several precautions should be considered to ensure safe use of Lenalidomide.

• Pregnancy risk: drug is contraindicated in pregnancy due to teratogenic potential; ensure effective contraception.
• Renal function: dose adjustment may be required in patients with impaired renal clearance.
• Hematologic monitoring: regular blood counts are essential to detect cytopenias.
• Thromboembolic prophylaxis: assess need for anticoagulation in high‑risk patients.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations of lenalidomide.
• Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia.
• Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• P-glycoprotein inhibitors (e.g., verapamil): may increase lenalidomide exposure.
• Immunosuppressants (e.g., cyclosporine): may augment immunomodulatory effects.
• Hormonal contraceptives: effectiveness may be reduced; consider additional barrier methods.